Amylin inhibits ovariectomy-induced bone loss in rats
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Amylin (AMY), a peptide co-secreted with insulin by pancreatic beta-cells, inhibits bone resorption and stimulates osteoblastic activity. The ovariectomized (OVX) rat is an established animal model for human osteoporosis. Thus, the present experiment was performed to study the effects of AMY on estrogen deficiency-induced bone loss in rats. Thirty-one 6-month-old Wistar rats were randomized by body weight (BW) into two groups. The first underwent surgical OVX (n=21). The second was sham-operated (SH; n=10). Sixty days after surgery, 11 OVX rats were s.c. injected with rat AMY (3 microg/100 g BW/day, for 30 days; OVX+AMY), and 10 with solvent alone in the same way (0.15 ml/100 g BW; OVX). Each rat, housed in an individual cage, was fed daily the mean quantity of diet consumed the day before by SH rats. This diet contained 0.24% calcium and 0. 16% phosphorus. The 31 animals were killed on day 90. No difference in daily weight gain and BW was observed between groups. Neither AMY treatment nor OVX had any significant effect upon femoral morphology, femoral failure load, diaphyseal femoral density (representative of cortical bone) and total femoral calcium content. Nevertheless, both distal metaphyseal (representative of cancellous bone) and total femoral bone densities were higher in SH and OVX+AMY than in OVX rats. The highest plasma osteocalcin concentration was measured in OVX+AMY rats. Simultaneously, urinary deoxypyridinoline excretion was lower in OVX+AMY than in OVX rats. These results indicate that in OVX rats, AMY treatment inhibited trabecular bone loss both by inhibiting resorption and by stimulating osteoblastic activity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In this experimental model, amylin reduced urinary excretion of deoxypyridinoline and reduced trabecular bone loss, whereas it had no effect on cortical bone indices (101).”
From The Activity of Peptides of the Calcitonin Family in Bone (2019) · cites this paper as [101]
Citations
Cites
Biochemical and Biophysical Research Communications
(1960) · Nature · doi:10.1038/186124d0 · Cited by 6,700
RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor
McLatchie, L. M., Fraser, N. J., Main, M. J., Wise, A., Brown, J., Thompson, N., Solari, R., Lee, M. G., & Foord, S. M. (1998) · Nature · doi:10.1038/30666 · Cited by 2,134
The ovariectomized rat model of postmenopausal bone loss
Kalu, D. N. (1991) · Bone and Mineral · doi:10.1016/0169-6009(91)90124-i · Cited by 1,361
Cooper, G. J., Willis, A. C., Clark, A., Turner, R. C., Sim, R. B., & Reid, K. B. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.23.8628 · Cited by 1,299
Trends in Endocrinology and Metabolism 1998
Brines, R. (1998) · Trends in Endocrinology & Metabolism · doi:10.1016/s1043-2760(98)00013-7 · Cited by 699
Christopoulos, G., Perry, K. J., Morfis, M., Tilakaratne, N., Gao, Y., Fraser, N. J., Main, M. J., Foord, S. M., & Sexton, P. M. (1999) · Molecular Pharmacology · doi:10.1124/mol.56.1.235 · Cited by 486 · cited 1×
“Their pharmacology has recently been shown to be produced by the co-expression of calcitonin C1a receptors and receptor activity modulating protein (RAMP1) (Muff et al. 1995, Christopoulos et al. 1999 ) in a manner similar to the formation of CGRP receptor from calcitonin receptor-related receptor and RAMP1 (MacLatchi…”
ResultCytokines and Estrogen in Bone: Anti-Osteoporotic Effects
Horowitz, M. C. (1993) · Science · doi:10.1126/science.8480174 · Cited by 453 · cited 1×
“The loss of estrogen at menopause creates an imbalance of osteoblastic and osteoclastic activities such that bone resorption outpaces bone formation (Dempster & Lindsay 1993, Horowitz 1993 ) leading to high turnover bone loss, post-menopausal osteoporosis and increased risk of fractures.”
BackgroundAvian osteoclasts as estrogen target cells.
Oursler, M. J., Osdoby, P., Pyfferoen, J., Riggs, B. L., & Spelsberg, T. C. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.15.6613 · Cited by 395 · cited 1×
“Osteoclasts contain estrogen receptors and respond to estrogen in vitro by decreasing resorptive activity ( Oursler et al. 1991, 1994 ) and blocking the production of proinflammatory cytokines by bone marrow and bone cells (Pacifici 1998).”
BackgroundDempster, D., Lindsay, R., Dempster, & Lindsay (1993) · The Lancet · doi:10.1016/0140-6736(93)90570-7 · Cited by 356 · cited 1×
“The loss of estrogen at menopause creates an imbalance of osteoblastic and osteoclastic activities such that bone resorption outpaces bone formation ( Dempster & Lindsay 1993, Horowitz 1993) leading to high turnover bone loss, post-menopausal osteoporosis and increased risk of fractures.”
BackgroundBone Density in Non-Insulin-Dependent Diabetes Mellitus: The Rotterdam Study
van Daele, P. L. A., Stolk, R. P., Burger, H., Algra, D., Grobbee, D. E., Hofman, A., Birkenhager, J. C., & Pols, H. A. P. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-6-199503150-00002 · Cited by 308
High affinity amylin binding sites in rat brain.
Beaumont, K., Kenney, M. A., Young, A. A., & Rink, T. J. (1993) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)13212-4 · Cited by 208 · cited 1×
“AMY receptors of the type found in nucleus accumbens (Beaumont et al. 1993) and area postrema have been elusive.”
BackgroundSelf-citationAmylin secretion from the rat pancreas and its selective loss after streptozotocin treatment.
Ogawa, A., Harris, V, McCorkle, S. K., Unger, R. H., & Luskey, K. L. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114528 · Cited by 205 · cited 1×
“AMY is mostly expressed in pancreatic -cells, from which it is co-secreted with insulin in response to nutrient stimuli (Ogawa et al. 1990).”
BackgroundHuman giant cell tumors of the bone (osteoclastomas) are estrogen target cells.
Oursler, M. J., Pederson, L., Fitzpatrick, L., Riggs, B. L., & Spelsberg, T. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.12.5227 · Cited by 201
Editorial: Cytokines, Estrogen, and Postmenopausal Osteoporosis—The Second Decade
Pacifici, R. (1998) · Endocrinology · doi:10.1210/endo.139.6.6087 · Cited by 194 · cited 1×
“1991, 1994) and blocking the production of proinflammatory cytokines by bone marrow and bone cells (Pacifici 1998).”
BackgroundCook, J. G. H. (1975) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1177/000456327501200162 · Cited by 165 · cited 1×
“This assay was based on a modified Jaffé method in which picric acid forms a colored solution in the presence of creatinine (Cook 1975).”
MethodMuff, R., Born, W., & Fischer, J. A. (1995) · European Journal of Endocrinology · doi:10.1530/eje.0.1330017 · Cited by 156 · cited 1×
“Their pharmacology has recently been shown to be produced by the co-expression of calcitonin C1a receptors and receptor activity modulating protein (RAMP1) ( Muff et al. 1995, Christopoulos et al. 1999) in a manner similar to the formation of CGRP receptor from calcitonin receptor-related receptor and RAMP1 (MacLatchi…”
ResultPreclinical pharmacology of pramlintide in the rat: Comparisons with human and rat amylin
Young, A. A., Vine, W., Gedulin, B. R., Pittner, R., Janes, S., Gaeta, L. S. L., Percy, A., Moore, C. X., Koda, J. E., Rink, T. J., et al. (1996) · Drug Development Research · doi:10.1002/(sici)1098-2299(199604)37:4<231::aid-ddr5>3.0.co;2-m · Cited by 135 · cited 1×
“injection employed in the present experiment is predicted from kinetic studies (Young et al. 1996) to have raised plasma AMY concentrations to a supraphysiological 1 nM, the mean increment in 24 h exposure to circulating AMY can be calculated to be approximately 35 pM, a 2- to 3-fold increase over physiological concen…”
MethodSelf-citationAmylin Stimulates Osteoblast Proliferation and Increases Mineralized Bone Volume in Adult Mice
Cornish, J., Callon, K. E., Cooper, G. J. S., & Reid, I. R. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.1163 · Cited by 126 · cited 2×
“In addition, AMY has potent effects to lower plasma calcium (Ca) concentration and inhibit osteoclast activity (Datta et al. 1989, MacIntyre 1989), and is reported to stimulate osteoblast growth ( Cornish et al. 1995, 1998b, Romero et al. 1995).”
BackgroundIn vivo and in vitro effects of amylin and amylin-amide on calcium metabolism in the rat and rabbit
Datta, H. K., Zaidi, M., Wimalawansa, S. J., Ghatei, M. A., Beacham, J. L., Bloom, S. R., & MacIntyre, I. (1989) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(89)92391-7 · Cited by 114
Cornish, J., Callon, K. E., King, A. R., Cooper, G. J. S., & Reid, I. R. (1998) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1998.275.4.e694 · Cited by 102
Pastoureau, P., Chomel, A., & Bonnet, J. C. (1995) · Osteoporosis International · doi:10.1007/bf02106092 · Cited by 95
Amylinʼs physiology and its role in diabetes
Young, A. A. (1997) · Current Opinion in Endocrinology and Diabetes · doi:10.1097/00060793-199708000-00006 · Cited by 87
Self-citationBiochemical markers for assessing skeletal growth.
Robins, S. P. (1994) · PubMed · Cited by 72
Alam, A. S. M. T., Bax, C. M. R., Shankar, V. S., Bax, B. E., Bevis, P. J. R., Huang, C. L.-H., Moonga, B. S., Pazianas, M., & Zaidi, M. (1993) · Journal of Endocrinology · doi:10.1677/joe.0.1360007 · Cited by 62
AMYLINAMIDE, BONE CONSERVATION, AND PANCREATIC β CELLS
Macintyre, I. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91028-3 · Cited by 56 · cited 1×
“In addition, AMY has potent effects to lower plasma calcium (Ca) concentration and inhibit osteoclast activity (Datta et al. 1989, MacIntyre 1989 ), and is reported to stimulate osteoblast growth (Cornish et al. 1995, 1998b, Romero et al. 1995).”
BackgroundDissociation of the effects of amylin on osteoblast proliferation and bone resorption
Cornish, J., Callon, K. E., Lin, C. Q.-X., Xiao, C. L., Mulvey, T. B., Coy, D. H., Cooper, G. J. S., & Reid, I. R. (1998) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1998.274.5.e827 · Cited by 54
Osteoporosis following calcium deficiency in rats
Salomon, C. D. (1971) · Calcified Tissue International · doi:10.1007/bf02010150 · Cited by 51
Amylin regulation of carbohydrate metabolism
Young, A., Pittner, R. A., Gedulin, B. R., Vine, W., & RINK, T. J. (1995) · Biochemical Society Transactions · doi:10.1042/bst0230325 · Cited by 49 · cited 1×
“1987) and to the calcitonins at the N- and C-termini (Young et al. 1995).”
BackgroundSelf-citationMechanisms of bone resorption in calcium-deficient rats
SISSONS, H. A., Kelman, G. J., & Marotti, G. (1984) · Calcified Tissue International · doi:10.1007/bf02405394 · Cited by 46
Editorial: Cytokines, Estrogen, and Postmenopausal Osteoporosis--The Second Decade
Pacifici, R. (1998) · Endocrinology · doi:10.1210/en.139.6.2659 · Cited by 36
Amylin increases bone volume but cannot ameliorate diabetic osteopenia
Romero, D. F., Bryer, H. P., Rucinski, B., Isserow, J. A., Buchinsky, F. J., Cvetković, M., Liu, C. C., & Epstein, S. (1995) · Calcified Tissue International · doi:10.1007/bf00298745 · Cited by 35
Amylin in bone conservation current evidence and hypothetical Considerations
Zaidi, M., Shankar, V. S., Huang, C. L.-H., Pazianas, M., & Bloom, S. R. (1993) · Trends in Endocrinology and Metabolism · doi:10.1016/1043-2760(93)90095-v · Cited by 30 · cited 2×
“The lack of AMY in type 1 diabetes mellitus has been proposed as a mechanism explaining susceptibility to osteopenia in those patients (Zaïdi et al. 1993) and treatment of type 1 diabetic subjects for 1 year with the AMY agonist pramlintide resulted in improvement of biochemical bone markers (Bone et al.”
BackgroundMelton, L. J. (1994) · CPOBGYN. Clinical perspectives in obstetrics and gynecology · doi:10.1007/978-1-4612-4330-4_8 · Cited by 9
The Ovariectomized Rat: A Model for Postmenopausal Osteoporosis?
Erben, R. G., Kohn, B., Weiser, H., & Rambeck, W. A. (1992) · Springer eBooks · doi:10.1007/978-3-642-76766-1_80 · Cited by 2
Cited by
Relationships between fat and bone
Reid, I. R. (2008) · Osteoporosis International · doi:10.1007/s00198-007-0492-z · Cited by 475
“Its systemic administration substantially increases bone volume in mice [67] and rats [ 68 , 69], and the amylin knockout mouse has reduced bone density [70].”
BackgroundAmylin: Pharmacology, Physiology, and Clinical Potential
Hay, D. L., Chen, S., Lutz, T. A., Parkes, D. G., & Roth, J. D. (2015) · Pharmacological Reviews · doi:10.1124/pr.115.010629 · Cited by 400
Type 2 diabetes and the skeleton: new insights into sweet bones
Shanbhogue, V. V., Mitchell, D. M., Rosen, C. J., & Bouxsein, M. L. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00283-1 · Cited by 237
The Impact of Diabetes and Diabetes Medications on Bone Health
Gilbert, M. P., & Pratley, R. E. (2015) · Endocrine Reviews · doi:10.1210/er.2012-1042 · Cited by 209
“ficiency has been shown to lead to bone loss in mice, and treatment with amylin can partially reverse osteopenia in ovariectomized rats (127, 128).”
The Activity of Peptides of the Calcitonin Family in Bone
Naot, D., Musson, D. S., & Cornish, J. (2019) · Physiological Reviews · doi:10.1152/physrev.00066.2017 · Cited by 141
“In this experimental model, amylin reduced urinary excretion of deoxypyridinoline and reduced trabecular bone loss, whereas it had no effect on cortical bone indices (101).”
Background
Metadata
- Authors
- Horcajada-Molteni, M., Davicco, M., Lebecque, P., Coxam, V, Young, A., & Barlet, J.
- Affiliations
- Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement (FR)
- ORCID
- Coxam, V
- Venue
- Journal of Endocrinology
- Publisher
- Bioscientifica
- Published
- 2000-06-01
- Volume
- 165
- Issue
- 3
- Pages
- 663-668
- ISSN
- 0022-0795 (ISSN-L)
- 1479-6805
- OpenAlex
- W2158977547
- Cited by
- 40
- References
- 34
- Citations by year
- 2026: 1 · 2020: 4 · 2019: 2 · 2018: 3 · 2016: 1 · 2015: 5 · 2014: 1 · 2012: 2
- FWCI
- 1.88
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Medicinal Plant Pharmacodynamics Research
- Keywords
- amylin, ovariectomy, bone loss, osteoporosis, estrogen deficiency, bone resorption, osteoblast activity, trabecular bone, bone mineral density, osteocalcin, deoxypyridinoline, femur, bone formation markers
- MeSH terms
- Amino Acids, Amyloid, Animals, Calcium, Disease Models, Animal, Female, Femur, Humans, Ovariectomy, Stress, Mechanical, Osteoporosis, Postmenopausal, Osteocalcin, Rats, Wistar, Rats, Islet Amyloid Polypeptide
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.